

Supporting information

Mesoporous vesicles from supramolecular helical peptide as drug cargo


Sibaprasad Maity, Poulami Jana, Suman kumar Maity and Debasish Halder*

Department of Chemical Sciences, Indian Institute of Science Education and Research –Kolkata,
Mohanpur, West Bengal- 741252, India.


E-mail: deba_h76@yahoo.com

Table of contents


ESI Figure S1 and S2	2	Figure S8	13
ESI Figure S3	3	Figure S9	14
ESI Figure S4 and S5	4	Figure S10	15
ESI Figure S6 and S7	5	Figure S11	16
ESI Figure S8	6	Figure S12	17
Figure S1	6	Figure S13	18
Figure S2	7	Figure S14	19
Figure S3	8	Figure S15	20
Figure S4	9	Figure S16	21
Figure S5	10	Figure S17	22
Figure S6	11	Figure S18	23
Figure S7	12	Figure S19	24




ESI Figure S1: TGA graph of peptide **1** microvesicles from MeOH.



ESI Figure S2: DSC curve of peptide **1** microvesicles from MeOH.




ESI Figure S3: Circular dichroism spectra of peptide **1** in methanol solution.




ESI Figure S4: (a) Wide angle PXRD pattern of peptide **1** vesicles from MeOH and (b) X-ray powder pattern from single crystal data of peptide **1**.




ESI Figure S5: DLS data of drug unloaded vesicle at concentration 1 mg/ml (green) and drug loaded vesicles at same concentration (red).




ESI Figure S6: EDS data of drug loaded peptide vesicles.



ESI Figure 7: UV-Visible spectra of sulfamethoxazole drug release from peptide vesicles at pH 6.2 (sodium phosphate buffer).



ESI Figure 8: AFM image showing ruptured vesicle after fast release of encapsulated drug in phosphate buffer at pH 5.



Scheme 1: Reactions and conditions: a) dry DCM, H-Aib-OMe, DCC, HOBT, 0°C, 77.8% b) NaOH(2N), MeOH, HCl c) dry DCM, H-Phe-OMe, DCC, HOBT, 0°C, 78.8% d) dry DCM, H-Phe-OMe, DCC, HOBT, 0°C, 72.3% e) dry DCM, H-Aib-OMe, DCC, HOBT, 0°C, 82.9%

Figure S1: Schematic presentation of synthesis of pentapeptide 1.




Figure S2: ¹H NMR (DMSO-*d*₆, 500 MHz, δ_{ppm}) spectra of Boc-Leu-OH




Figure S3: ^{13}C NMR ($\text{DMSO-}d_6$, 125 MHz, δ_{ppm}) spectra of Boc-Leu-OH




Figure S4: ^1H NMR (CDCl_3 , 500 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-OMe




Figure S5: ^{13}C NMR (CDCl_3 , 125 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-OMe




Figure S6: ^1H NMR ($\text{DMSO-}d_6$, 500 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-OH




Figure S7: ^{13}C NMR (DMSO- d_6 , 125 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-OH




Figure S8: ^1H NMR (CDCl_3 , 500 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-Phe-OMe





Figure S9: ¹³C NMR (CDCl₃, 125 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-Phe-OMe






Figure S10: ^1H NMR (DMSO- d_6 , 500 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-Phe-OH




Figure S11: ^{13}H NMR (DMSO- d_6 , 125 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-Phe-OH




Figure S12: ^1H NMR (CDCl_3 , 500 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-Phe-Phe-OMe




Figure S13: ^{13}C NMR (CDCl_3 , 125 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-Phe-Phe-OMe




Figure S14: ^1H NMR (DMSO- d_6 , 500 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-Phe-Phe-OH




Figure S15: ^{13}C NMR (DMSO-*d*₆, 125 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-Phe-Phe-OH




Figure S16: ¹H NMR (CDCl₃, 500 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-Phe-Phe-Aib-OMe




Figure S17: ^{13}C NMR (CDCl_3 , 125 MHz, δ_{ppm}) spectra of Boc-Leu-Aib-Phe-Phe-Aib-OMe




Figure S18: Mass spectra of pentapeptide 1




Figure S19: (a) and (b) Confocal microscopic images of Rhodamine 6G encapsulated peptide **1** microvesicles. (c) 3D image of peptide **1** vesicles from AFM, (d) Microvesicles of peptide **1** by FE-SEM; and (e) AFM image of ruptured microvesicles of peptide **1** after release of encapsulated drug in phosphate buffer at pH 5.